Every material Form 8-K Healthpeak Properties has filed with the SEC since July 25, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Healthpeak Properties reported third quarter 2026 net income of $0.02 per share and diluted FFO as Adjusted of $0.44 per share. The company raised its full year 2026 FFO as Adjusted and same-store cash NOI guidance ranges while lowering its diluted EPS guidance due to acquisition-related depreciation. Shareholders also saw active leasing across outpatient medical and lab segments alongside strategic acquisitions.
Diluted net income of $0.02 per share and diluted FFO as Adjusted of $0.44 per share for the third quarter of 2026.
Raised full year 2026 diluted FFO as Adjusted per share guidance to a range of $1.76 to $1.78.
Janus Living reported third quarter revenue of $268 million, up 78% compared to the prior year quarter.
Net Debt to Adjusted EBITDAre was 4.7x for the quarter ended September 30, 2026.
Healthpeak reported second quarter 2026 results on August 4, 2026, with total revenues of $771.6 million, up from $694.3 million a year earlier, and diluted earnings of $0.08 per share, up from $0.05. The company raised its full-year 2026 diluted earnings and diluted FFO as Adjusted guidance by $0.02 per share at the midpoint, and its quarterly FFO as Adjusted per share was flat at $0.46.
Q2 2026 diluted EPS was $0.08 versus $0.05 a year earlier; diluted FFO as Adjusted per share was $0.46, unchanged from the prior year.
2026 diluted EPS guidance is $0.48 to $0.52, up from $0.46 to $0.50; diluted FFO as Adjusted guidance is $1.73 to $1.77, up from $1.71 to $1.75.
The Brookfield joint venture closed in July 2026 with proceeds of approximately $1.025 billion for a 49% interest in an 86-property outpatient medical portfolio.
The board authorized a new $500 million share repurchase program and declared a third-quarter dividend totaling $0.305 per share.
Healthpeak reported first-quarter 2026 diluted EPS of $0.28, up from $0.06 a year earlier, while diluted Nareit FFO fell to $0.42 per share from $0.45. The company raised its full-year 2026 diluted EPS guidance to $0.46 to $0.50 from $0.34 to $0.38 and lowered its Nareit FFO guidance to $1.68 to $1.72 from $1.70 to $1.74, while raising FFO as Adjusted guidance and reaffirming same-store NOI growth.
Q1 2026 diluted EPS $0.28 vs. $0.06 in Q1 2025; diluted Nareit FFO $0.42 vs. $0.45; diluted FFO as Adjusted $0.45 vs. $0.46.
2026 diluted EPS guidance raised to $0.46 to $0.50 from $0.34 to $0.38.
2026 Nareit FFO guidance lowered to $1.68 to $1.72 from $1.70 to $1.74; FFO as Adjusted guidance raised to $1.71 to $1.75 from $1.70 to $1.74.
Janus Living IPO in March 2026 generated approximately $880 million of net proceeds; Healthpeak owns 81.6% of Janus Living.
On March 23, 2026, concurrent with the Janus Living initial public offering, Healthpeak and its subsidiaries amended three credit agreements, with lenders consenting to the IPO. The Healthpeak term loan was amended to add a $400.0 million senior unsecured delayed draw facility and raise maximum borrowing capacity from $1.5 billion to $2.0 billion, with $750.0 million of unused capacity after closing.
New $400.0 million senior unsecured delayed draw term loan facility with a five-year stated maturity
Healthpeak term loan maximum borrowing capacity raised from $1.5 billion to $2.0 billion
Initial margin on new facility is 0.80% for Term SOFR and Daily SOFR loans, based on current debt ratings
Revolver and Physicians Realty term loan amendments made no change to maturity, pricing or commitment amounts
Healthpeak reported fourth-quarter 2025 diluted net income of $0.16 per share, up from $0.01 a year earlier, while full-year 2025 net income fell to $0.10 per share from $0.36 in 2024. It set 2026 guidance of $0.34 to $0.38 per share for diluted earnings and $1.70 to $1.74 per share for Nareit FFO, which is below the $1.81 it reported for 2025. The company also plans an initial public offering of Janus Living, a senior housing REIT, expected in the first half of 2026.
Q4 2025: net income $0.16 per share vs. $0.01 a year earlier; Nareit FFO $0.47 vs. $0.44; AFFO $0.40 vs. $0.44
Full-year 2025: net income $0.10 per share vs. $0.36 in 2024; Nareit FFO $1.81 vs. $1.61
2026 guidance: diluted EPS $0.34 to $0.38; Nareit FFO $1.70 to $1.74 per share
Board declared $0.305 per share in dividends for Q1 2026; Janus Living IPO expected in the first half of 2026
Healthpeak reported a third-quarter 2025 net loss applicable to common shares of $117.3 million, or $0.17 per share, compared with net income of $85.7 million, or $0.12 per share, a year earlier. The loss reflects $175.8 million of impairment charges on unconsolidated joint ventures. The company cut its full-year 2025 diluted earnings per share guidance to $0.00 to $0.06 from $0.25 to $0.31, while reaffirming its Nareit FFO guidance of $1.78 to $1.84 per share.
Third-quarter Nareit FFO rose to $0.45 per share from $0.44 a year earlier; FFO as Adjusted was $0.46 versus $0.45.
Third-quarter net loss of $117.3 million ($0.17 per share) included $175.8 million of impairments on unconsolidated joint ventures.
2025 diluted EPS guidance lowered to $0.00 to $0.06 from $0.25 to $0.31; Nareit FFO guidance of $1.78 to $1.84 reaffirmed.
Board declared monthly dividends of $0.10167 per share for October, November and December 2025, totaling $0.305 for the fourth quarter.
Healthpeak reported second-quarter 2025 diluted net income of $0.05 per share, down from $0.21 a year earlier, while Nareit FFO was $0.43 per share versus $0.44 and FFO as Adjusted and AFFO rose to $0.46 and $0.44 per share. The company cut its full-year 2025 diluted earnings per share guidance to $0.25 to $0.31 from $0.30 to $0.36 and Nareit FFO guidance to $1.78 to $1.84 from $1.81 to $1.87, while reaffirming its FFO as Adjusted guidance of $1.81 to $1.87 per share.
Q2 2025 diluted net income was $0.05 per share versus $0.21 in Q2 2024.
Q2 2025 Nareit FFO was $0.43 per share versus $0.44; FFO as Adjusted was $0.46 versus $0.45; AFFO was $0.44 versus $0.40.
2025 diluted EPS guidance lowered to $0.25 to $0.31 from $0.30 to $0.36; Nareit FFO guidance lowered to $1.78 to $1.84 from $1.81 to $1.87.
Monthly dividend of $0.10167 per share declared for July, August and September 2025, totaling $0.305 for the third quarter; approximately $2.3 billion of liquidity as of July 24, 2025.
Healthpeak reported first quarter 2025 results, with net income applicable to common shares of $42.4 million, or $0.06 per diluted share, up from $6.5 million, or $0.01, a year earlier. Diluted Nareit FFO rose to $0.45 per share from $0.27, and the company reaffirmed its full-year 2025 guidance, including diluted earnings per share of $0.30 to $0.36.
Q1 2025 diluted net income of $0.06 per share versus $0.01 in Q1 2024; diluted Nareit FFO of $0.45 versus $0.27
Diluted FFO as Adjusted of $0.46 per share versus $0.45; diluted AFFO of $0.43 versus $0.42
2025 guidance reaffirmed: diluted EPS of $0.30 to $0.36 and diluted Nareit FFO of $1.81 to $1.87 per share; monthly dividend of $0.10167 per share for April, May and June
Healthpeak Properties appointed Kelvin O. Moses as Chief Financial Officer and principal financial officer, effective April 24, 2025, under the company's succession plan. Mr. Moses previously served as Executive Vice President – Investments and Portfolio Management and joined the company in 2018. The filing discloses his $550,000 base salary and equity awards, a CFO change that shareholders will want to track.
Kelvin O. Moses appointed CFO and principal financial officer, effective April 24, 2025
Base salary of $550,000, plus eligibility for short-term and long-term incentive plans
Retentive equity award with grant date fair value of $380,000 and performance-based award of $570,000
Accounting, treasury and investor relations leaders remain in place, per the press release
Healthpeak Properties said Chief Financial Officer Peter Scott resigned, effective on notice given April 2, 2025, to become Chief Executive Officer of Healthcare Realty Trust Incorporated (NYSE: HR). The company said the resignation was not due to any disagreement with the company or its external auditor, and Scott is not entitled to severance. The company has a succession plan and expects to name an internal successor in the coming weeks.
Scott informed the company of his resignation on April 2, 2025; the filing and press release are dated April 7, 2025.
Scott is leaving to become CEO of Healthcare Realty Trust Incorporated (NYSE: HR).
Scott is not entitled to any severance payment under the Executive Severance Plan or otherwise.
The company expects to name an internal successor for CFO in the coming weeks.
Healthpeak Properties announced that Chief Operating Officer Thomas Klaritch will retire, stepping down as COO and leader of the outpatient medical segment on March 1, 2025, and leaving employment on September 30, 2025. He will then provide consulting services through the end of 2025 for a fee of $50,000 per month, and his retirement benefits are conditioned on signing a Retirement and Release Agreement. The change affects senior management leadership and the outpatient medical segment, but the filing gives no financial results or guidance.
Klaritch steps down as COO and outpatient medical segment leader effective March 1, 2025
Employment terminates September 30, 2025; consulting services from October 1 to December 31, 2025 at $50,000 per month
Benefits include prorated 2025 bonus based on the average of prior three years' bonuses and prorated 2025 equity awards through September 30, 2025
Benefits are conditioned on signing a Retirement and Release Agreement filed as Exhibit 10.1
Healthpeak reported fourth-quarter 2024 net income of $0.01 per share, down from $0.13 a year earlier, and Nareit FFO of $0.44 per share, down from $0.48, while FFO as Adjusted of $0.46 and AFFO of $0.40 per share were up or flat from the prior year. The company also gave 2025 guidance, including diluted earnings per share of $0.30 to $0.36, and raised its quarterly dividend 1.7% to $0.305 per share, with a planned switch to monthly payments starting April 2025.
Q4 2024 net income of $0.01 per share vs $0.13 in Q4 2023; Q4 total revenues of $697,988 thousand vs $553,652 thousand
Q4 2024 Nareit FFO of $0.44 per share vs $0.48; AFFO of $0.40 vs $0.36
2025 guidance: diluted EPS $0.30 to $0.36 and Nareit FFO $1.81 to $1.87 per share, vs 2024 full-year Nareit FFO of $1.61
Dividend raised to $0.305 per share; monthly dividend expected from April 2025; COO Tom Klaritch and GC Jeff Miller depart December 31, 2025
Healthpeak Properties amended and extended its $3 billion senior unsecured revolving credit facility, with the new maturity set at January 19, 2029, and made conforming changes to two term loans. The filing describes routine refinancing terms, with pricing and covenants substantially consistent with the prior agreement, and does not report any change in profit or guidance.
Revolving facility matures January 19, 2029, with two optional six-month extensions
Borrowing capacity can be increased to up to $3.75 billion, subject to conditions
Interest at SOFR plus 0.775% and facility fee of 0.15% based on current debt ratings
Covenants include Consolidated Tangible Net Worth of at least $7.7 billion, tested quarterly
Healthpeak Properties reported third-quarter 2024 results in which AFFO rose to $0.41 per share from $0.40 a year earlier, while Nareit FFO fell to $0.44 from $0.46 and net income was flat at $0.12 per share. The company raised several full-year 2024 guidance ranges, including diluted earnings per share to $0.40 to $0.42 from $0.27 to $0.31, and declared a $0.30 quarterly dividend.
Q3 2024 AFFO of $0.41 per share versus $0.40 in Q3 2023; Nareit FFO of $0.44 versus $0.46; net income of $0.12 per share, unchanged.
2024 diluted EPS guidance raised to $0.40 to $0.42 from $0.27 to $0.31; AFFO guidance raised to $1.56 to $1.58 from $1.54 to $1.58.
Quarterly common dividend of $0.30 per share declared October 23, 2024, payable November 15, 2024 to holders of record on November 4, 2024.
Expected 2024 merger-related synergies raised to approximately $50 million from the Physicians Realty Trust merger.
Healthpeak Properties reported second-quarter 2024 results on July 25, 2024, with diluted net income of $0.21 per share, up from $0.09 a year earlier, while Nareit FFO was $0.44 per share, down from $0.45. The company raised its full-year 2024 diluted earnings per share guidance to $0.27 to $0.31 from $0.16 to $0.20. For shareholders, higher earnings guidance is offset in part by a slight decline in FFO per share, a key REIT measure.
Q2 2024 diluted net income of $0.21 per share vs. $0.09 in Q2 2023; Nareit FFO $0.44 vs. $0.45; AFFO $0.39 vs. $0.40
Full-year 2024 diluted EPS guidance raised to $0.27 to $0.31 from $0.16 to $0.20; diluted Nareit FFO guidance raised to $1.59 to $1.63 from $1.56 to $1.60
Quarterly common dividend of $0.30 per share declared July 24, 2024, payable August 16, 2024, to holders of record on August 5, 2024
New $500 million share repurchase authorization effective through July 2026, replacing the existing authorization
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Healthpeak Properties filing is on SEC EDGAR ↗. 8-K briefs of other companies →